

chain nodes :

12 13 14 15 16 17 18 19 20 21 22 24

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

2-6 2-22 3-13 3-14 4-15 4-20 5-16 5-21 7-19 8-18 9-24 11-12 16-17

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11

exact/norm bonds :

1-2 1-5 2-3 2-6 3-4 4-5 4-15 6-7 6-11 7-8 8-9 9-10 9-24 10-11 11-12

exact bonds :

2-22 3-13 3-14 4-20 5-16 5-21 7-19 8-18 16-17

G1:O,NH

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS13:CLASS14:CLASS15:CLASS16:CLASS17:CLASS18:CLASS19:CLASS20:CLASS21:CLASS22:CLASS24:CLASS

1978071503

FILE 'PEAKSY' ENTERED AT 15:01:44 ON 27 DEC 2007
STRUCTURE UPLOADED
S B LI CME BAR
S S LI PUBL
FILE 'CAPLES' ENTERED AT 15:02:41 ON 27 DEC 2007
S B LI

Comparing via minnows 19 533

MARCH 1993 VOL 20 / NO 3 / ISSN 0898-2603

1500000000

OPTIONAL FORMS 1, 2, 3, OR 7-22

1990-1991: *Journal of the American Academy of Child and Adolescent Psychiatry* (JACAP) 29(12): 1829-1830.

HEMS 1	2 AUG 06	Web Page for BTM Seminar Schedule - N. America
HEMS 2	2 AUG 06	CAS PREDICTOR enhanced with new experimental property tags
HEMS 3	2 AUG 06	TBTB enhanced with new therapeutic edition
HEMS 4	6 AUG 13	CA/Caplus enhanced with additional kind codes for granted patents
HEMS 5	8 AUG 13	CA/Caplus enhanced with CAS indexing in pre-1967 records
HEMS 6	8 AUG 13	Full-text patent databases enhanced with predefined patent (family) display formats from MPNADCCB
HEMS 7	8 AUG 13	DEPATENTED now available on STM
HEMS 8	8 AUG 13	CAS REGISTRY enhanced with additional experimental spectral property data
HEMS 9	8 SEP 13	STM Analyst, Version 2.0, now available with Derwent World Patents Index
HEMS 10	8 SEP 13	PPDB renamed to 36P13
HEMS 11	13 SEP 13	MPNADCCB enhanced with monthly SII frequency
HEMS 12	13 SEP 13	CA/Caplus enhanced with printed CA page images from 1967-1998
HEMS 13	13 SEP 13	Capplus coverage extended to include traditional medicine patents
HEMS 14	13 SEP 13	BASEB, EUSL, and LIPMESSAGE reloaded with enhancements
HEMS 15	13 OCT 02	CA/Caplus enhanced with pre-1967 records from Chemisches Reichsbüro
HEMS 16	15 OCT 13	HALSTENSM updated with new compounds
HEMS 17	15 OCT 13	Govt. Indian patent publication number format enhanced
HEMS 18	15 OCT 13	PPDB enhanced with XML display format
HEMS 19	15 OCT 13	PPDB released with enhancements
HEMS 20	16 OCT 13	LNPNADCCB now available on STM
HEMS 21	16 OCT 13	HALSTENSM pricing structure to change
HEMS 22	16 OCT 13	MPNADCCB added to additional database clusters
HEMS 23	16 OCT 13	LNPNADCCB removed from database clusters and STM
HEMS 24	16 OCT 13	GENOME now includes more than 10 million sequences
HEMS 25	16 OCT 13	PPNCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
HEMS 26	16 OCT 13	MEMLINE and LIPMESSAGE updated with 2008 MeSH vocabulary
HEMS 27	16 OCT 13	CA/Caplus enhanced with new custom IPC display formats
HEMS 28	16 OCT 13	STM Viewer enhanced with full-text patent content

NUWB BACKBES: AT SEPTEMBER 2007: CURRENT WINNOW VERSION IS V6.2, CURRENT MACINTOSH VERSION IS V6.0.00001 AND V6.0.01 (JP), CURRENT CAVIAR VERSION IS V6.0.00001 AND V6.0.01 (JP).

STN Operating Hours Plus Help Desk Availability
Welcome Banner and News Items
For general information regarding STN implementation of XFR

entitled NFPA followed by the item number or name to see notes on that specific topic.

All use of STN is subject to the provisions of the STN Customer Agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

1990 Columbia 13

10/22/03, 15:3

→ File New
Cost in U.S. Dollars
Full Estimated Cost

Since File Total
Entry Session
6,21 6,21

FILE 'REGISTRY' EDITED AT 15:14:44 ON 27 DEC 2003
THIS IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP SUBJECTS' FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the REGISTRY data file
provided by InfraChem.

STRUCTURE FILE DATES: 26 DEC 2003 HIGHEST NO 259582-76-7
DICTIONARY FILE DATES: 26 DEC 2003 HIGHEST NO 259582-75-2

NEW CAS information was received. Enter HELP DRACETPMS for details.

REGISTRY INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SMARTSEARCH searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.acs.org/support/stn/reg/properties.html>

Uploading C:\Program Files\STNexp\Queries\10828793-122707.eLR

11 STRUCTURE UPLOADED

12 0 11
13 0 0 ANSWERS
14 0 0

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRICE *
Structure attributes must be viewed using STN Express query preparation.

15 0 0 0 0 0 0 0
SEARCH SEARCH INITIATED 15:07:31 FILE 'REGISTRY'
SAMPLE SEARCH COMPUTED - 0 TO ITERATE

16 0 0 0 PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00:00:01

17 0 0 0 0 0 0 0
FILE FILE WORKED: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROCESSED ITERATIONS: 0 TO 0
PROCESSED ANSWERS: 0 TO 0

18 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0

19 0 0 0 0 0 0 0
FILE SEARCH INITIATED 15:07:31 FILE 'REGISTRY'
FILE SEARCH COMPUTED - 00 TO ITERATE

20 0 0 0 0 0 0 0
SEARCH SEARCH INITIATED 15:07:31 FILE 'REGISTRY'
SEARCH TIME: 00:00:01

21 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0

→ File capture
Cost in U.S. Dollars
Full Estimated Cost

Since File Total
Entry Session
172,55 172,76

FILE 'CAPTURE' EDITED AT 15:14:44 ON 27 DEC 2003
THIS IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP SUBJECTS' FOR DETAILS.

REGISTRY

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PR) field (available for records published or updated in Chemical Abstracts after December 31, 1981), unless otherwise indicated in the original publications. The CAS Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

CASE COVERED 1997 - 27 Dec 2007 VOL 147 186 26
FILE LAST UPDATED: 26 Dec 2007 (0091276/BC)

Effective October 17, 2007, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/inforpol/cy.html>

→ 8 33

1.0 1.8

→ d via abs histix 1-19 14

LN: ANF0001 1 OF 16 CAPTION COPYRIGHT 2007 ACS on STN
2007/12/27/25 CAPLOS

DN: 147441654

TI: characterization of the Metabolic Activation of Hepatitis C Virus
HCV-6130: Inhibition of 2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine
(PSI-6130) and Identification of a Novel Active 5'-Triphosphate Species
AU: Ma, Ren-Jiang; Wen-Hong; Bolindu; Nicolas; Leveque, Vincent; Ali, Samit;
Lata, Selma; Farouk; Masjedizadeh, Mohammad; Smith, David S.; Casmack,
Nack; Klimp, Klaus; Symon, Julian

CH: Rocca, Palo Alto 94304, CA, USA

DN: Journal of Biological Chemistry (2007), 282(41), 29812-29820

DOI: 10.1074/jbc.M612958JBC

PR: American Society for Biochemistry and Molecular Biology

PP: Journal

LA: English

AB: 2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine (PSI-6130) is a potent inhibitor of hepatitis C virus (HCV) replication in the subgenomic RNA replicon system, and its corresponding 5'-triphosphate is a potent inhibitor of the HCV RdRp polymerase in vitro. In this study the formation of PSI-6130-triphosphate was characterized in primary human hepatocytes. PSI-6130 and its 5'-phosphorylated衍生物, were identified, and the intracellular concon. were determined. In addition, the deaminated derivative of PSI-6130, 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine (RQ2433, PSI-6202), and its corresponding phosphorylated metabolites were identified in human hepatocytes after incubation with PSI-6130. The formation of the 5'-triphosphate (TP) of PSI-6130 (PSI-6130-TP) and RQ2433 (RQ2433-TP) increased with time and reached steady state levels at 48 h. The formation of both PSI-6130-TP and RQ2433-TP demonstrated a linear relationship with the extracellular concen. of PSI-6130 up to 100 μM, suggesting a high capacity of human hepatocytes to generate the two triphosphates. The mean half-lives of PSI-6130-TP and RQ2433-TP were 4.7 and 18 h, resp. RQ2433-TP also inhibited RNA synthesis by the native HCV replicase isolated from HCV replicon cells and the recombinant HCV polymerase NS5B with potencies comparable with those of PSI-6130-TP. Incorporation of RQ2433-5'-monophosphate (MP) into nascent RNA by NS5B led to chain termination similar to that of PSI-6130-TP. These results demonstrate that PSI-6130 is metabolized to two pharmaco. active species in primary human hepatocytes.

BT: 82204-44-7, PSI-6130-triphosphate


PT: BMB (Biological study, unclassified); PAC (Pharmacological activity); PPT (Pharmacokinetics); THU (Therapeutic use); BIDL (Biological study); BDB (Dose)

TI: characterization of metabolic activation of hepatitis C virus
HCV-6130: Inhibition of 2'-Deoxy-2'-C-Methylcytidine
(PSI-6130) and identification of a novel active 5'-triphosphate
S10071003

DN: 82204-44-7 CAPLOS

AB: Cytidine 5'-[tetrahydrogen triphosphate], 2'-Deoxy-2'-L-Deoxy-2'-methyl-
(2'R)-[C8] (GDXE NAME)

Absolute stereochemistry.



17 L17264-33-4, PBI-6130

PL: DNA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); TBU (Therapeutic use); BIDL (Biological study); USES (Uses):

(characterization of metabolic activation of hepatitis C virus nucleoside inhibitor β -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (PBI-6130) and identification of a novel active 5'-triphosphate isomer)

RN: 817264-33-4, CAPLUE

CN: Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.REF. 25 THREE ARE 25 CITED REFERENCES AVAILABLE FOR THIS PREDIGESTED CITATION AVAILABLE IN THE RD FORMAT

LA NUMBER 2 OF 10 CAPLUE. COPYRIGHT 2007 EMBL on STN
RN 817264-33-4, CAPLUE

CD 1471397801

TI Pharmacokinetics of the antiviral agent β -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in rhesus monkeys

AU Abidi, Ghazaleh; Barzani, Bahman J.; Shi, Junxing; Hernandez-Santiago, Brenda L.; Schinazi, Raymond F.

CR Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA

OO Antimicrobial Agents and Chemotherapy (2007), 51(8), 2877-2882

COUNCIL: AMERICAN; ISSN: 0893-6504

ED American Society for Microbiology

DP Journal

LA English

AB β -D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PBI-6130) is an effective inhibitor of hepatitis C virus (HCV) replication *in vitro*. The purpose of this study was to evaluate the single-dose pharmacokinetics of PBI-6130 in rhesus monkeys following i.v. and oral administration. Noncompartmental analysis of the serum data obtained following oral and i.v. administration was performed. Pharmacokinetic studies with rhesus monkeys indicated slow and incomplete absorption with a mean absorption time (MAT) of 4.6 h and an oral bioavailability of 24.9 ± 18.3% (mean ± standard deviation), with comparable mean apparent half-lives following i.v. (4.54 ± 3.98 h) and oral (5.04 ± 1.13 h) administrations. The average percentages of the total dose excreted unchanged and in deaminated form in the urine were 22.3% ± 22.6% and 16.9% ± 6.6% (n = 1) and 6.0% ± 3.9% and 3.7% ± 1.8% (n = 1), resp. The total bioavailability, taking into account the parent drug and its deaminated metabolite 2'-deoxy-2'-fluoro-2'-C-methylcytidine (PBI-6061), was 6.4% ± 2.6%. PBI-6130 was present in the cerebrospinal fluid after oral and i.v. dosing. However, no deamination of radiolabelled PBI-6130 was detected after 8 h of incubation in monkey and human white blood. An *in-vitro* deaminase product of PBI-6130 (PBI-6061) was orally administered to monkeys, but it failed to improve the oral bioavailability of PBI-6130. Further studies are warranted to improve the oral bioavailability and reduce the deamination of PBI-6130 in order to

explore the potential of this drug for the treatment of HIV-infected individuals.


RE 86329-66-2

RLI 130 (Biological study, unclassified); B101 (Biological study); (PSI-6206) pharmacokinetics of antiviral deoxyfluoromethylcytidine in rhesus monkeys

RI 86329-66-2 CAPLUS

CM Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 950923-07-6

RLI PET (Pharmacokinetics); RRI (Synthetic preparation); THU (Therapeutic use); B101 (Biological study); PREP (Preparation); UHSS (Uses); (PSI-6206) pharmacokinetics of antiviral deoxyfluoromethylcytidine in rhesus monkeys

PM 650923-07-6 CAPLUS

CN 140362 NMR DSC YER KESTIGERU

Absolute stereochemistry.



IT 817204-33-5 PET-613B

RLI PET (Pharmacokinetics); THU (Therapeutic use); B101 (Biological study); UHSS (Uses); (pharmacokinetics of antiviral deoxyfluoromethylcytidine in rhesus monkeys)

PM 817204-33-5 CAPLUS

CM Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REF.CNT 23 WHERE RAB 23 CITED REFERENCE AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LA3 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS on 3TN

BN 6671446693 CAPLUS

DP 14151513


PT Preparation of arylated 1'-(P)-2'-deoxy-2'-fluoro-2'-methylcytidines as antiviral agents

RE Chung, Byung-Moon; Choi, Jeong-Hi; Baena, Keshab; Hong, Paljuwan

PA Hoffmann-La Roche A.-A., switz.: Pharmasset Inc.

(b) *Preparation of acylated (2'-R)-2'-deoxy-2'-fluoro-2'-methylcytidine as a trifluoroacetyl ester*
 4-(2,2,2-trifluoroethyl)-2,2-dimethylpropanoate (2'-R)-2'-deoxy-2'-fluoro-2'-methylcytidine, λ -deoxy-2'-fluoro-2'-methyl-, 3',5'-diphosphate, (2'-R)-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-trifluoroacetyl ester

DISCUSSION: A CONCLUDING REMARK




NC 940908-72-2 CNFLHS
 CN cyclohexane, 2'-[2-methoxy-2'-methoxy-2-methyl-, 2',5'-bis(2-methoxylpropanoate), (2'R)] (C INDEX NAME)

Additional grants are available for research.




PN: 940098-80-5 CARKUS
 CP: Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, 1',5'-bis(2-methylpropyl
 esterone), 7'-oxo - (CA INDEX NAME)

સાધુવું હોય એ કોરન્ટિસ મુખ્યમાની હોય.



BN 980908-82-7 CAPABG
 Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(propyl carbamate), hydrochloride (1:1) (DA NIMOX BANK)

◎ 2005 年 1 月 1 日起施行。本文档系对本行的内部规定。



• HCl

1T 81104-53-4

RL: RCT (Reactant); PACT (Reactant or reagent)
(preparation of acylated (2'R)-2'-deoxy-2'-fluorocytidines as
nucleophilic agents)

2N 81104-53-6 CAPLUS

3M Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Racemic (+).

6B-CIT 2 THREE ARE 2 CITED REFERENCES AVAILABLE FOR THIS PRD900
ALL CITATIONS AVAILABLE IN THE RS FORMAT

LA 81104-53-6 CAPLUS COPYRIGHT 2007 ACT on STN

2007-11-05 08:00 CAPLUS

148-397251

2T Mechanism of activation of β -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine
and inhibition of hepatitis C virus RNA polymerase3D Mihalikoski, Eriko; Rao, Baiyiqing; Komugi, Mangelia; McCrayer, Tamara R.;
McCrayer, Tong; Niclousovic Steiner, Holly M.; Schinazi, Raymond F.;
Dowling, Steven J.; Ghosh, Aleksandra; Oster, Michael J.; Yerushalmi, Phillip
A.

4B Pharmasset, Inc., Princeton, NJ, 08546, USA

5G Antimicrobial Agents and Chemotherapy (2007), 51(2), 563-569

6DENI: 08400; ISSN: 0893-6504

7H American Society for Microbiology
Journal

8A Phytol

2'-Fluoro-2'-C-methylcytidine (PSI-6130) is a potent
specific inhibitor of hepatitis C virus (HCV) RNA synthesis in Huh-7
replicon cells. To inhibit the HCV 4839 RNA polymerase, PSI-6130 must be
phosphorylated to the 5'-triphosphate form. The phosphorylation of
PSI-6130 and inhibition of HCV RNA were investigated. The
phosphorylation of PSI-6130 by recombinant human 2'-deoxycytidine kinase
(hCK) and uridine-cytidine kinase 1 (hUCK-1) was measured by using a
coupled spectrophotometric reaction. PSI-6130 was shown to be a substrate
for purified hCK, with a Km of 81 μ M and a $Kcat$ of 0.007 s⁻¹, but was
not a substrate for hUCK-1. PSI-6130 monophosphate (PSI-6130-MP) was
efficiently phosphorylated to the diphosphate and subsequently to the
triphosphate by recombinant human DMP-CMP kinase and uridine
diphosphate kinase, resp. The inhibition of wild-type and mutated (S282T)
HCV 4839 RNA polymerases was studied. The steady-state inhibition constants
(Ki) for PSI-6130 triphosphate (PSI-6130-TP) with the wild-type enzyme was
2.3 μ M. Similar results were obtained with 2'-C-methyladenosine
triphosphate (Ki = 1.5 μ M) and 2'-C-methylcytidine triphosphate (Ki =
1.1 μ M). HCV with the S282T mutation, which is known to confer
resistance to 2'-C-methyladenosine, was inhibited by PSI-6130-TP as
efficiently as the wild-type. Incorporation of PSI-6130-TP into RNA

as measured by purified MSS RNA polymerase resulted in chain termination. S17264-44-1, PET 613G triphosphate 932727-63-6, PSS 6130

nonphosphonate 9:2721-66-7, PSX 8120 aliphosphate

Rez. 1950. Ethnological study, unclassified; 1951. (Biological) study;

Information: mechanism of activation of $\text{Pd}(\text{O}-\text{C}_6\text{H}_4-\text{CH}_2-\text{CH}_2-\text{CF}_3)_4$


ANTIBODY TO LYSINE AND INHIBITION OF hepatitis C virus NS5B RNA-polymerase

300 812499-04-0 CARLOS

Chemical structure of 2'-deoxy-2'-fluoro-2'-methyl-5'-trityluridine.

SEARCH INDEX NAME


Algebraic Topology: Homotopy and Homology



2022-09-05 16:45:27

5,5'-Benzodiphenylidene acid, 2,2'-deoxy-2,2'-difluoro-2,2'-methylene-, (2R,2S)- (IUPAC INDEX: FAMES-1)


Algebraic structures



2020 RELEASE UNDER E.O. 14176

INN: 9321-04-7 CASRN: 100-00-0
CN: cytidine 5'-trihydrogen diphosphate), 2'-deoxy-2'-fluoroc-3'-methyl-, (2R)- (1S) INDEX NAME:

60001128 2013-06-11 14:12



XII 82 NUMBER 3796, 1991 6119

1971-1972: epizootiological studies, unclassified: PRE-EPIDEMIC SURVEY

PCT AND PULMONARY
BIOLOGICAL STUDY

4.2.2. Activation of actin by β -D-2'-deoxy-2'-methylene- β -D-glucosidase

Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, Maryland 20205.

Algebra 1: Semester 2, Page 100 of 101



RECORD 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE PORTAT


CA ANSWER 5 OF 10 CAPTION COPYRIGHT 2007 ACS ON STN
20081965301 CAPTION
DB 1451505487
PT Synthesis of 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranose
AU Clark, Jeremy L.; Mason, J.; Christian Bobbe, Ann J.; Hollcker, Laurent;
Chimie, Raymond Y.
CD Pharmacia, Inc., Tucker, GA, USA
SO Journal of Carbohydrate Chemistry (2006), 25(6), 467-476
PQDN: JCCOM; ISSN: 0732-8303
PH Taylor & Francis, Inc.
DT Journal
LA English
GS CASREACT 105:505497
AB The synthesis of Me 3,5-di-O-benzyl-2-deoxy-2-fluoro-7-C-methyl-D-ribofuranoside and the conversion to the corresponding 3-O-acetyl-3,5-di-O-benzyl-2-deoxy-2-fluoro-2-C-methyl-D-ribofuranose and 1,3,5-(*t*-Bu₃N₂)-O-benzyl-2-deoxy-2-fluoro-2-C-methyl-D-ribofuranone is reported. The key synthetic step is the fluorination of the tertiary center of Me 3,5-di-O-benzyl-2-C-methyl-D-ribofuranoside to provide Me 3,5-di-O-benzyl-2-deoxy-2-fluoro-2-C-methyl-D-ribofuranoside.
RP 81284-31-0 B74C38-94-59
HL BBD (synthetic preparation); PRMP (Preparation;
(synthesis of 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranose via
fluorination of the tertiary center of Me 3,5-di-O-benzyl-2-C-methyl-
D-ribofuranosides)
RC 81284-32-3 CAPTION
CN Guidine, G-benzoyl-2'-deoxy-7'-fluoro-2'-methyl-, 3',5'-dibenzoset,
(2'R)- (7C1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



CA 81284-34-5 CAPTION
Benzamide, N-[1-[(2R)-1-(di-O-benzoyl-2-deoxy-2-methyl-D-
ribofuranosyl)-1,2-dihydro-2-oxo-6-pyrimidinyl]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RECORD 30 THERE ARE NO CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE PORTAT

CA ANSWER 4 OF 10 CAPTION COPYRIGHT 2007 ACS ON STN
20091478128 CAPTION

PC 145-202057
PI inhibition of hepatitis C replicon RNA synthesis by N-(2'-deoxy-2'-fluoro-2'-C-methyluridylate) is specific inhibitor of hepatitis C virus replication

AB: Breyer, Lieven J.; McBrearty, Tamara P.; Thornish, Phillip M.; Clevy, Torrey; Hollister, Laurent; Lontia, Sufonica; Nachman, Tammy; Gier, Jason; Bennett, Matthew A.; Xie, Meng-Yu; Chhinaid, Raymond P.; Morley, Tom D.; Juander, Justin L.; Furman, Phillip A.; Otto, Michael J.

Q3 Pharmasset Inc, Princeton, NJ, USA
No Antiviral Chemistry & Chemotherapy (2006), 22(2), 79-87

ANSWERING QUESTIONS

© International Medical Press, Ltd

EN English
 PR β -D-2'-Deoxy-2'-C-methylcytidine (PGL-6130) is a cytidine analog with potent and selective anti-Hepatitis C virus (HCV) activity in the subgenomic HCV replicon assay. 99% effective concentration (EC90) = $6.6 \pm 2.0 \mu\text{M}$. The spectrum of activity and cytotoxicity profile of PGL-6130 was evaluated against a diverse panel of viruses and cell types, and against two adult, HCV-1b replicons. The S282T mutation, which confers resistance to 2'-C-Me adenosine and other 2'-methylated nucleosides, showed only a 1.5-fold increase in EC90. When assayed for activity against bovine diarrhoea virus (BDV), which is typically used as a surrogate assay to identify compounds active against HCV, PGL-6130 showed no anti-BDV activity. Weak antiviral activity was noted against other flaviviruses, including West Nile virus, Canyon type 2, and yellow fever virus. These results indicate that PGL-6130 is a specific inhibitor of HCV. PGL-6130 showed little or no cytotoxicity against various cell types, including human peripheral blood mononuclear and human bone marrow progenitor cells. No mitochondrial toxicity was observed with PGL-6130. The reduced activity against the RdRp S282T mutant suggests that PGL-6130 is an inhibitor of replicon RNA synthesis. Finally, the no-effect dose for mice treated i.p. with PGL-6130 for six consecutive days was >100 mg/kg.

1511-6136 (Inhibition of hepatitis C replicon RNA synthesis) 812264-30-A CAPIUS

2011-01-12 10:00:00 - 2011-01-12 10:00:00



PLATE 36 THREE ARE 36 CITED REFERENCES AVAILABLE FOR THIS PEGOPA
SERIAL NUMBER. REFER TO THE INDEX IN THIS FILE FOR DETAILS.

1.4 AMBIANCE 7 OF 10 CAPTUS COPYRIGHT 2007 MCS on CIN
1.4 CODE:265472 CAPTUS

144-11239
 TA Preparation of silyl-substituted 7-deoxy-2-fluoro-L-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone nucleosides as potential antiviral agents

112 Cuan, Beiping-Kuofu; Wang, Peiyuan

VA Chamaeleo, Inc., Bus
SO PCT Int. Appl., 74 sp.
CROSS-REF'D?

PT Patent
LA English
PAP/CHT 1
PARENT NO. KIND DATE APPLICATION NO. DATE
P1 90 2006031725 A2 20060323 162005-16-2666 20060323
20060323 20060323 162005-16-2666 20060323



LA ANSWER 8 OF 10 CAULOS COPYRIGHT 2007 ACS on STM
 200611010884 CAPLUS
 PU 144-1771198
 TI Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purine nucleoside analogs via condensation of the lactone to nucleosides as potential antiviral agents

1G Wang, Peiyun; Sier, Wojciech; Clark, Jeremy; Chen, Ryoung-Keon; Shu, Junxiang; Hu, Jinfu
 PH Pharmacia, Inc., BBR
 DO MCT Int. Appl., 34 pp.

CA2645115A1
 DT Patent
 LB English

PAW, PCT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 2006012446	A2	20060202	WO 2005-0825916	20050721
BR 2006012446	A3	20060727		
M1 AB, AG, AL, AM, AT, DE, DK, ES, BA, FR, BG, BR, BY, BE, CA, CM, CN, CG, GB, CD, CZ, DE, DK, ES, EC, EP, EL, ES, FI, GB, GD, GB, GR, HN, HU, IS, IN, IS, JV, ME, KG, ME, MP, FR, ME, LG, LE, LB, LS, CR, ID, LV, MB, MD, MG, MK, MN, MM, MR, ME, RS, SI, PG, PR, OM, EG, PL, PT, NO, RU, SC, SO, SE, SG, SK, SL, SM, SZ, TJ, TN, TR, TW, UA, DE, US, UK, VN, YU, BA, TM, TM RU, RO, SE, BG, CB, CY, CZ, DE, DK, ES, PT, PR, GB, GR, HU, IS, IS, IT, LT, LU, LV, NL, PL, PT, RO, SE, SI, SK, TR, MP, RU, CP, CO, CL, CH, CA, CN, GQ, GW, GL, MK, ME, MU, PG, TG, HM, OM, PA, MD, LS, MR, ME, ND, SD, SL, SN, TZ, US, KW, AM, AR, BX, EG, ES, OM, PG, YU, VN				
RU 2005267051	A1	20060202	RU 2005-267051	20050721
CN 2174651	A1	20060202	CN 2005-2574651	20050721
BR 1771858	A2	20070416	BR 2005-175359	20050721
M1 AT, BE, BG, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IS, IS, IT, LU, LV, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101023094	A	20070822	CN 2005-80034530	20050721
US 2006149721	A1	20050907	US 2006-333597	20060212
BR 2006000005	A	20070706	BR 2007-FR655	20070220
PRH1 2004-59986-P	S	20040721		
CN 04-59986-P	P	20040909		
US 2005-189498	A1	20050721		
BR 2005-0025916	W	20050721		
M1 BR-EP 144-1771198				
SI				

* STRUCTURE DISPLAY TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for preparing of 2-deoxy-2-fluoro-2-methyl-D-ribonolactones, λ , wherein λ can independently be H, CH₃, acetyl, benzoyl, pivaloyl, 4-nitrobenzoyl, 3-nitrobenzoyl, 2,6-dinitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chloroacetylbenzoyl, 4-methoxybenzoyl, 3-methoxybenzoyl, 2-methoxybenzoyl, benzyl, 4-methoxybenzyl, trityl, trialkylsilyl, t-butyl-dimethylsilyl, t-butyldiphenylsilyl, TIPS, THP, PMB, or MEM are prepared and used in the condensation to 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purine nucleoside analogs, where, 2-maxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs M and X1, where X is a halogen; Y is N or CH; Z is a halogen.

hydroxyl, ether, thio, thionether, (un)substituted amine or alkyli; R^1 is alkyl, vinyl, ethynyl; R^2 and R^3 can be same or different; R_1 is alkyl, vinyl, acyl, cyclic acetate such as 2',3'-O-isopropylidene or 2',3'-O-mannofuranosylidene; R^4 , R^5 , and R^6 are independently H, halogen, hydroxyl, ether, thio, thionether, thionether, (un)substituted amine, (un)substituted amido, alkyli, halogenated alkynyl, alkenyl, halogenated alkenyl, alkyne, halogenated alkynyl, hydroxyl alkyl, alkoxy are prepared and are potential anti-HIV agents. Specifically, IV was prepared (no yield, claimed) via condensation, alkylation and stereoselective fluorination reactions and can exhibit potential use as an anti-HIV agent.

1P 617204-32-3P 617204-35-4P 874638-62-1P

874638-94-3P 874638-99-3P

RU TMP (Industrial manufacturer); 3PM (Synthetic preparation); 2RER (Preparation)

Preparation of alkyl-substituted 2'-deoxy-2'-fluoro-D- α -holuransyl pyrimidines and purine nucleoside analogs via condensation of the lactone to nucleosides;

RU 617204-32-1 CAPLUS

4P Cytidine, N-holurayl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzosate, (2'R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RU 617204-32-4 CAPLUS

CA Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RU 874638-97-1 CAPLUS

CA 2-(2R)-5-O-phenyl-2'-deoxy-2'-fluoro-2'-methyl-3-O-(methylsulfonyl)-D- α -holurano-pentofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl- (407) (CA INDEX NAME)

Absolute stereochemistry.



RE: 874438-94-5 CAPLUS

CN: Benzoate, 2-[(1-[2P]-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2'-methyl)-2'-C-oxido-pentofuranosyl]-1,2-dihydro-2H-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry:



RE: 874438-98-7 CAPLUS

CN: Cytidine, 2'-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry:



LA: ABS/EP 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AM: 20050404160 CAPLUS

DN: 1451248667

TI: Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-Fluoro-2'-C-methyl-Cytidine, a Potent Inhibitor of Hepatitis C Virus Replication

AU: Clark, Jeremy L.; Bolleret, Laurent; Mezon, J. Christian; Stuyver, Lieven; Thurnherr, Phillip M.; Louch, Stefania; Mohrayer, Tamara R.; Schinazi, Raymond F.; Malanoff, Kyoko; Otar, Michael J.; Pernar, Phillip A.; Stein, Weijun; Tsi, Patterson, Steven E.; Frankiewicz, Krzysztof W.

CL: Pharmaceuticals, Inc., Princeton, NJ, 08543, USA

JG: Journal of Medicinal Chemistry (2008), 48(17), 5504-5508

(DOI: 10.1016/j.jmedchem.2008.02.2623)

PB: American Chemical Society

DD: (Journal)

LA: English

DE: C68P/C6CT 1451248667

AB: The pyrimidine nucleoside, 2'-deoxy-2'-fluoro-2'-C-methylcytidine (I) was designed as a hepatitis C virus RNA-dependent RNA polymerase (HCV RdRp) inhibitor. The title compound was obtained by a DAST fluorination of 4-methoxy-1-(2'-methyl-3,5-di-O-benzoyl-β-D-ribofuranosyl)cytosine to provide 1-(2'-methyl-3,5-di-O-benzoyl-2'-fluoro-2'-methyl)-1,2-d-O-benzoyl-β-D-ribofuranosylcytosine. The protected 2'-C-methylcytidine was obtained as a byproduct from the DAST fluorination and utilized for the preparation of two biologically active compounds, from a common precursor. Compound I and 2'-C-methylcytidine were assayed in a sub-genomic HCV replicon assay system and found to be potent and selective inhibitors of HCV replication. Compound I shows increased inhibitory activity in the HCV replicon assay compared to 2'-C-methylcytidine and low cellular toxicity.

ID: 817204-73-49

RE: HCV (pharmacological activity); PCT (Reaction); SDN (Synthetic preparation); ZBG (biological study); PkBP (Preparation); RNCT (Reactant or reagent)

(reaction, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of hepatitis C virus replication)

BN 972264-3-6 CAPADS
 C121316, 2'-deoxy-2-(fluorovinyl)-, (2'R)- (CA INDEX NAME)

Physical Examination. Position 10.




(7) $\{6, 13, 20, 26, 33, 40\}$

PL: PA (Pharmacological activity); SP: (Synthetic preparation); BICL (Biological study); PREP (Preparation);
 (668) 2-(6-aminohexyl)-2'-furo[2,3-*c*]-2-methylcytidine, a potent inhibitor of hepatitis C virus replication

卷之二 二五三 122-4,6-2 CARLUS

ON Uridine, 2'-mido-2'-fluoro-2'-methyl-, (2'R)- (90%) (CA INDEX: 16611)

Resonance at quenching energy, rotation (4).



11. *Phragmites australis* (L.) Trin. ex Stev. (Cyperales: Phragmataceae) (Fig. 11)

P11 PCT (Reactant); SPM (Synthetic preparation); PRSP (Preparation); PACT (Reactant or reagent);
 (design, synthesis via fluorination, and antiviral activity of
 2'-deoxy-2'-fluoro-2'-O-methyl-cytidine, a potent inhibitor of
 Herpesvirus C virus replication)

1955 45-17254-32-13 588712

CN Cyclospine, 8-oxo-2²-deoxy-2¹-fluoro-2¹-methyl-, 1¹,5¹-dibenzoate, (2²R)- [14531-16-1] (CA INDEX NAME)


Absolute stereochemistry. Resolution (4).



2020 RELEASE UNDER E.O. 14176

Uridine, 3'-deoxy-2'-fluoro-2'-methyl-, 5',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

absolute stereochemistry. Rotation (i).



(T) 617264-38-9P

PL: SKM (synthetic preparation); PPRP (Preparation: design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)

DN: 97264-38-9 CAPLUS

CR: Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'-R)- (9CI) (CA INDEX NAME)

Anticarcinogenicity, Rotaxane (+).



RNU

● RDX

PL.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE PORTER

LA: ABSTRACT IS IN THE CAPTION (COPPIPIONE 2007 ACE OR STN)
 AB: 2005-134765 CAPLUS
 DN: 14219407A
 TT: Preparation of modified thiomoxinate 2'-R-2'-deoxy-2'-fluoro-2'-O-methyl nucleoside analogs as antiviral agents
 IN: Clark, Jerome
 PA: Sharmasoft, Ltd., Barbados
 SO: PCT int. appl., 228 pp.
 COUN: PCT0202

UF: Patent
 LA: English
 DAH.CNT: 1

PATENT NO.	INVENTOR	DATE	APPLICATION NO.	DATE
EP 1208909147	Me	20050113	EP 2004-0812472	20040421
WO 200503147	A3	20050303		
Me, AZ, AL, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52, A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104, A105, A106, A107, A108, A109, A110, A111, A112, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156, A157, A158, A159, A160, A161, A162, A163, A164, A165, A166, A167, A168, A169, A170, A171, A172, A173, A174, A175, A176, A177, A178, A179, A180, A181, A182, A183, A184, A185, A186, A187, A188, A189, A190, A191, A192, A193, A194, A195, A196, A197, A198, A199, A200, A201, A202, A203, A204, A205, A206, A207, A208, A209, A210, A211, A212, A213, A214, A215, A216, A217, A218, A219, A220, A221, A222, A223, A224, A225, A226, A227, A228, A229, A230, A231, A232, A233, A234, A235, A236, A237, A238, A239, A240, A241, A242, A243, A244, A245, A246, A247, A248, A249, A250, A251, A252, A253, A254, A255, A256, A257, A258, A259, A260, A261, A262, A263, A264, A265, A266, A267, A268, A269, A270, A271, A272, A273, A274, A275, A276, A277, A278, A279, A280, A281, A282, A283, A284, A285, A286, A287, A288, A289, A290, A291, A292, A293, A294, A295, A296, A297, A298, A299, A300, A301, A302, A303, A304, A305, A306, A307, A308, A309, A310, A311, A312, A313, A314, A315, A316, A317, A318, A319, A320, A321, A322, A323, A324, A325, A326, A327, A328, A329, A330, A331, A332, A333, A334, A335, A336, A337, A338, A339, A340, A341, A342, A343, A344, A345, A346, A347, A348, A349, A350, A351, A352, A353, A354, A355, A356, A357, A358, A359, A360, A361, A362, A363, A364, A365, A366, A367, A368, A369, A370, A371, A372, A373, A374, A375, A376, A377, A378, A379, A380, A381, A382, A383, A384, A385, A386, A387, A388, A389, A390, A391, A392, A393, A394, A395, A396, A397, A398, A399, A400, A401, A402, A403, A404, A405, A406, A407, A408, A409, A410, A411, A412, A413, A414, A415, A416, A417, A418, A419, A420, A421, A422, A423, A424, A425, A426, A427, A428, A429, A430, A431, A432, A433, A434, A435, A436, A437, A438, A439, A440, A441, A442, A443, A444, A445, A446, A447, A448, A449, A450, A451, A452, A453, A454, A455, A456, A457, A458, A459, A460, A461, A462, A463, A464, A465, A466, A467, A468, A469, A470, A471, A472, A473, A474, A475, A476, A477, A478, A479, A480, A481, A482, A483, A484, A485, A486, A487, A488, A489, A490, A491, A492, A493, A494, A495, A496, A497, A498, A499, A500, A501, A502, A503, A504, A505, A506, A507, A508, A509, A510, A511, A512, A513, A514, A515, A516, A517, A518, A519, A520, A521, A522, A523, A524, A525, A526, A527, A528, A529, A530, A531, A532, A533, A534, A535, A536, A537, A538, A539, A540, A541, A542, A543, A544, A545, A546, A547, A548, A549, A550, A551, A552, A553, A554, A555, A556, A557, A558, A559, A560, A561, A562, A563, A564, A565, A566, A567, A568, A569, A570, A571, A572, A573, A574, A575, A576, A577, A578, A579, A580, A581, A582, A583, A584, A585, A586, A587, A588, A589, A589, A590, A591, A592, A593, A594, A595, A596, A597, A598, A599, A599, A600, A601, A602, A603, A604, A605, A606, A607, A608, A609, A609, A610, A611, A612, A613, A614, A615, A616, A617, A618, A619, A619, A620, A621, A622, A623, A624, A625, A626, A627, A628, A629, A629, A630, A631, A632, A633, A634, A635, A636, A637, A638, A639, A639, A640, A641, A642, A643, A644, A645, A646, A647, A648, A649, A649, A650, A651, A652, A653, A654, A655, A656, A657, A658, A659, A659, A660, A661, A662, A663, A664, A665, A666, A667, A668, A669, A669, A670, A671, A672, A673, A674, A675, A676, A677, A678, A679, A679, A680, A681, A682, A683, A684, A685, A686, A687, A688, A689, A689, A690, A691, A692, A693, A694, A695, A696, A697, A698, A699, A699, A700, A701, A702, A703, A704, A705, A706, A707, A708, A709, A709, A710, A711, A712, A713, A714, A715, A716, A717, A718, A719, A719, A720, A721, A722, A723, A724, A725, A726, A727, A728, A729, A729, A730, A731, A732, A733, A734, A735, A736, A737, A738, A739, A739, A740, A741, A742, A743, A744, A745, A746, A747, A748, A749, A749, A750, A751, A752, A753, A754, A755, A756, A757, A758, A759, A759, A760, A761, A762, A763, A764, A765, A766, A767, A768, A769, A769, A770, A771, A772, A773, A774, A775, A776, A777, A778, A779, A779, A780, A781, A782, A783, A784, A785, A786, A787, A788, A789, A789, A790, A791, A792, A793, A794, A795, A796, A797, A798, A799, A799, A800, A801, A802, A803, A804, A805, A806, A807, A808, A809, A809, A810, A811, A812, A813, A814, A815, A816, A817, A818, A819, A819, A820, A821, A822, A823, A824, A825, A826, A827, A828, A829, A829, A830, A831, A832, A833, A834, A835, A836, A837, A838, A839, A839, A840, A841, A842, A843, A844, A845, A846, A847, A848, A849, A849, A850, A851, A852, A853, A854, A855, A856, A857, A858, A859, A859, A860, A861, A862, A863, A864, A865, A866, A867, A868, A869, A869, A870, A871, A872, A873, A874, A875, A876, A877, A878, A879, A879, A880, A881, A882, A883, A884, A885, A886, A887, A888, A889, A889, A890, A891, A892, A893, A894, A895, A896, A897, A898, A899, A899, A900, A901, A902, A903, A904, A905, A906, A907, A908, A909, A909, A910, A911, A912, A913, A914, A915, A916, A917, A918, A919, A919, A920, A921, A922, A923, A924, A925, A926, A927, A928, A929, A929, A930, A931, A932, A933, A934, A935, A936, A937, A938, A939, A939, A940, A941, A942, A943, A944, A945, A946, A947, A948, A949, A949, A950, A951, A952, A953, A954, A955, A956, A957, A958, A959, A959, A960, A961, A962, A963, A964, A965, A966, A967, A968, A969, A969, A970, A971, A972, A973, A974, A975, A976, A977, A978, A979, A979, A980, A981, A982, A983, A984, A985, A986, A987, A988, A989, A989, A990, A991, A992, A993, A994, A995, A996, A997, A998, A998, A999, A999, A1000, A1001, A1002, A1003, A1004, A1005, A1006, A1007, A1008, A1009, A1009, A1010, A1011, A1012, A1013, A1014, A1015, A1016, A1017, A1018, A1019, A1019, A1020, A1021, A1022, A1023, A1024, A1025, A1026, A1027, A1028, A1029, A1029, A1030, A1031, A1032, A1033, A1034, A1035, A1036, A1037, A1038, A1039, A1039, A1040, A1041, A1042, A1043, A1044, A1045, A1046, A1047, A1048, A1049, A1049, A1050, A1051, A1052, A1053, A1054, A1055, A1056, A1057, A1058, A1059, A1059, A1060, A1061, A1062, A1063, A1064, A1065, A1066, A1067, A1068, A1069, A1069, A1070, A1071, A1072, A1073, A1074, A1075, A1076, A1077, A1078, A1079, A1079, A1080, A1081, A1082, A1083, A1084, A1085, A1086, A1087, A1088, A1089, A1089, A1090, A1091, A1092, A1093, A1094, A1095, A1096, A1097, A1098, A1098, A1099, A1099, A1100, A1101, A1102, A1103, A1104, A1105, A1106, A1107, A1108, A1109, A1109, A1110, A1111, A1112, A1113, A1114, A1115, A1116, A1117, A1118, A1119, A1119, A1120, A1121, A1122, A1123, A1124, A1125, A1126, A1127, A1128, A1129, A1129, A1130, A1131, A1132, A1133, A1134, A1135, A1136, A1137, A1138, A1139, A1139, A1140, A1141, A1142, A1143, A1144, A1145, A1146, A1147, A1148, A1149, A1149, A1150, A1151, A1152, A1153, A1154, A1155, A1156, A1157, A1158, A1159, A1159, A1160, A1161, A1162, A1163, A1164, A1165, A1166, A1167, A1168, A1169, A1169, A1170, A1171, A1172, A1173, A1174, A1175, A1176, A1177, A1178, A1179, A1179, A1180, A1181, A1182, A1183, A1184, A1185, A1186, A1187, A1188, A1189, A1189, A1190, A1191, A1192, A1193, A1194, A1195, A1196, A1197, A1198, A1198, A1199, A1199, A1200, A1201, A1202, A1203, A1204, A1205, A1206, A1207, A1208, A1209, A1209, A1210, A1211, A1212, A1213, A1214, A1215, A1216, A1217, A1218, A1219, A1219, A1220, A1221, A1222, A1223, A1224, A1225, A1226, A1227, A1228, A1229, A1229, A1230, A1231, A1232, A1233, A1234, A1235, A1236, A1237, A1238, A1239, A1239, A1240, A1241, A1242, A1243, A1244, A1245, A1246, A1247, A1248, A1249, A1249, A1250, A1251, A1252, A1253, A1254, A1255, A1256, A1257, A1258, A1259, A1259, A1260, A1261, A1262, A1263, A1264, A1265, A1266, A1267, A1268, A1269, A1269, A1270, A1271, A1272, A1273, A1274, A1275, A1276, A1277, A1278, A1279, A1279, A1280, A1281, A1282, A1283, A1284, A1285, A1286, A1287, A1288, A1289, A1289, A1290, A1291, A1292, A1293, A1294, A1295, A1296, A1297, A1298, A1298, A1299, A1299, A1300, A1301, A1302, A1303, A1304, A1305, A1306, A1307, A1308, A1309, A1309, A1310, A1311, A1312, A1313, A1314, A1315, A1316, A1317, A1318, A1319, A1319, A1320, A1321, A1322, A1323, A1324, A1325, A1326, A1327, A1328, A1329, A1329, A1330, A1331, A1332, A1333, A1334, A1335, A1336, A1337, A1338, A1339, A1339, A1340, A1341, A1342, A1343, A1344, A1345, A1346, A1347, A1348, A1349, A1350, A1351, A1352, A1353, A1354, A1355, A1356, A1357, A1358, A1359, A1359, A1360, A1361, A1362, A1363, A1364, A1365, A1366, A1367, A1368, A1369, A1369, A1370, A1371, A1372, A1373, A1374, A1375, A1376, A1377, A1378, A1379, A1379, A1380, A1381, A1382, A1383, A1384, A1385, A1386, A1387, A1388, A1389, A1389, A1390, A1391, A1392, A1393, A1394, A1395, A1396, A1397, A1398, A1398, A1399, A1399, A1400, A1401, A1402, A1403, A1404, A1405, A1406, A1407, A1408, A1409, A1409, A1410, A1411, A1412, A1413, A1414, A1415, A1416, A1417, A1418, A1419, A1419, A1420, A1421, A1422, A1423, A1424, A1425, A1426, A1427, A1428, A1429, A1429, A1430, A1431, A1432, A1433, A1434, A1435, A1436, A1437, A1438, A1439, A1439, A1440, A1441, A1442, A1443, A1444, A1445, A1446, A1447, A1448, A1449, A1449, A1450, A1451, A1452, A1453, A1454, A1455, A1456, A1457, A1458, A1459, A1459, A1460, A1461, A1462, A1463, A1464, A1465, A1466, A1467, A1468, A1469, A1469, A1470, A1471, A1472, A1473, A1474, A1475, A1476, A1477, A1478, A1479, A1479, A1480, A1481, A1482, A1483, A1484, A1485, A1486, A1487, A1488, A1489, A1489, A1490, A1491, A1492, A1493, A1494, A1495, A1496, A1497, A1498, A1498, A1499, A1499, A1500, A1501, A1502, A1503, A1504, A1505, A1506, A1507, A1508, A1509, A1509, A1510, A1511, A1512, A1513, A1514, A1515, A1516, A1517, A1518, A1519, A1519, A1520, A1521, A1522, A1523, A1524, A1525, A1526, A1527, A1528, A1529, A1529, A1530, A1531, A1532, A1533, A1534, A1535, A1536, A1537, A1538, A1539, A1539, A1540, A1541, A1542, A1543, A1544, A1545, A1546, A1547, A1548, A1549, A1549, A1550, A1551, A1552, A1553, A1554, A1555, A1556, A1557, A1558, A1559, A1559, A1560, A1561, A1562, A1563, A1564, A1565, A1566, A1567, A1568, A1569, A1569, A1570, A1571, A1572, A1573, A1574, A1575, A1576, A1577, A1578, A1579, A1579, A1580, A1581, A1582, A1583, A1584, A1585, A1586, A1587, A1588, A1589, A1589, A1590, A1591, A1592, A1593, A1594, A1595, A1596, A1597, A1598, A1598, A1599, A1599, A1600, A1601, A1602, A1603, A1604, A1605, A1606, A1607, A1608, A1609, A1609, A1610, A1611, A1612, A1613, A1614, A1615, A1616, A1617, A1618, A1619, A1619, A1620, A1621, A1622, A1623, A1624, A1625, A1626, A1627, A1628, A1629, A1629, A1630, A1631, A1632, A1633, A1634, A1635, A1636, A1637, A1638, A1639, A1639, A1640, A1641, A1642, A1643, A1644, A1645, A1646, A1647, A1648, A1649, A1649, A1650, A1651, A1652, A1653, A1654, A1655, A1656, A1657, A1658, A1659, A1659, A1660, A1661, A1662, A1663, A1664, A1665, A1666, A1667, A1668, A1669, A1669, A1670, A1671, A1672, A1673, A1674, A1675, A1676, A1677, A1678, A1679, A1679, A1680, A1681, A1682, A1683, A1684, A1685, A1686, A1687, A1688, A1689, A1689, A1690, A1691, A1692, A1693, A1694, A1695, A1696, A1697, A1698, A1698, A1699, A1699, A1700, A1701, A1702, A1703, A1704, A1705, A1706, A1707, A1708, A1709, A1709, A1710, A1711, A1712, A1713, A1714, A1715, A1716, A1717, A1718, A1719, A1719, A1720, A1721, A1722, A1723, A1724, A1725, A1726, A1727, A1728, A1729, A1729, A1730, A1731, A1732, A1733, A1734, A1735, A1736, A1737, A1738, A1739, A1739, A1740, A1741, A1742, A1743, A1744, A1745, A1746, A1747, A1748, A1749, A1749, A1750, A1751, A1752, A1753, A1754, A1755, A1756, A1757, A1758, A1759, A1759, A1760, A1761, A1762, A1763, A1764, A1765, A1766, A1767, A1768, A1769, A1769, A1770, A1771, A1772, A1773, A1774, A1775, A1776, A1777, A1778, A1779, A1779, A1780, A1781, A1782, A1783, A1784, A1785, A1786, A1787, A1788, A1789, A1789, A1790, A1791, A1792, A1793, A1794, A1795, A1796, A1797, A1798, A1798, A1799, A1799, A1800, A1801, A1802, A1803, A1804, A1805, A1806, A1807, A1808, A1809, A1809, A1810, A1811, A1812, A1813, A1814, A1815, A1816, A1817, A1818, A1819, A1819, A1820, A1821, A1822, A1823, A1824, A1825, A1826, A1827, A1828, A1829, A1829, A1830, A1831, A1832, A1833, A1834, A1835, A1836, A1837, A1838, A1839, A1839, A1840, A1841, A1842, A1843, A1844, A1845, A1846, A1847, A1848, A1849, A1849, A1850, A1851, A1852, A1853, A1854, A1855, A1856, A1857, A1858, A1859, A1859, A1860, A1861, A1862, A1863, A1864, A1865, A1866, A1867, A1868, A1869, A1869, A1870, A1871, A1872, A1873, A1874, A1875, A1876, A1877, A1878, A1879, A1879, A1880, A1881, A1882, A1883, A1884, A1885, A1886, A1887, A1888,				



The disclosed invention provides nucleoside analogs I, wherein B is purine and cytosine nucleoside; Z is G, C, CH₂, Ph, Me₂Ph, CNH, CH₂Ph; W is P(=O)(OR), Iodo; R is B, phosphate, N-phosphoryl, acyl, Ph, alkyl, carboxy, hydroxyl, sulfonate, ester, peptide, amino acid, amide, azide, R₁ and R₂ are independently B, alkyl, alkylene, alkynyl, vinyl, CH₂Ph, methylene, MeO, ester, acetoxy, thioalkyl, sulfoxide, sulfone; R₃ is alkyl, CH₃, Ph, Me, OEt, CH₂OM, CH₂Ph, Bz, CNH₂, CH₂NH₂, CH₂OBz, CH₂OBz₂, alkylene, and methods of treating a flavivirus infection, including hepatitis C virus, West Nile virus, yellow fever virus, and a rhinovirus infection in 3 hosts, including animals, and especially human, using a (2'-R)-2'-deoxy-2'-C-Me nucleosides, or a pharmaceutically acceptable salt, or prodrug thereof. Thus, (2'-R)-2'-deoxy-2'-fluoro-2'-C-methylcytidine was prepared and tested as antiviral agent. The effects the nucleoside analogs tested on human bone marrow cells are reported. (2'-Pn)-2'-deoxy-2'-fluoro-2'-C-methylcytidine shows activity against Rhinovirus, West Nile Virus, Yellow Fever virus, and Dengue virus. Cytotoxicity and effect of nucleoside analogs on human bone marrow cells are reported.

EP 1572033-1-AP
 EP: PAC (Pharmaceutical activity); RCT (Reactant); SGP (Synthetic preparation); THI (Therapeutic use); SIGE (Biological Study); PRBP (preparation); PACT (Reactant or reagent); DBRS (Uses);
 (preparation of modified fluorinated 2'-*tert*-2'-dioxoro-2'-fluoro-2'-C=O
 nucleoside analogs, or substituted analogs)



1.00 0.17 < 0.0 < 0.025

RIN (Pharmacological activity); SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

Preparation of modified fluorinated $(2'R)-2$ -deoxy- 2 -fluoro- 2 -C-Me nucleosides analogs as antiviral agents)



● HCl

IT B17204-46-7

Ph: PAC (pharmacological activity); TNU (therapeutic use); BIOL (Biological study); UMCB (User);
 Preparation of modified fluorinated 2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents;

RN B17204-46-7 CAYACS

ON Cyclidine 5'-[tertbutylhydrogen triphosphate], 2'-deoxy-2'-fluoro-2'-methyl-
 (2'R)- (CA INDEX NAME)

Absolute stereochemistry.




IT B17204-52-8P B17204-57-8P

Ph: RCT (Reagent); SPP (Synthetic preparation); RREP (Preparation); RACT (Reaction or reagent);
 Preparation of modified fluorinated 2'-deoxy-2'-fluoro-2'-C-Br nucleoside analogs as antiviral agents;

RN B17204-52-8 CAYACS

ON Cyclidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzate,
 (2'R)- (HCl) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN B17204-57-9 CAYACS

ON Cyclidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 2',5'-bis(trifluoromethoxy), (2'R)- (HCl) (CA INDEX NAME)

Absolute stereochemistry.

1Q7826,753



40 4 813

FILE 'HOME' ENTERED AT 15:01:03 ON 27 DEC 2007

FILE 'REGISTRY' ENTERED AT 15:01:44 ON 27 DEC 2007
STRUCTURE DOWNLOADED
L1 0 5 11 100 BAM
L2 19 3 11 100

FILE 'CAMPUS' ENTERED AT 15:02:41 ON 27 DEC 2007
L3 10 6 13